AMHR2-ED

AMHR2-ED refers to the **extracellular domain of the anti-Müllerian hormone receptor type II**. It is being developed and studied as an antigen for therapeutic cancer vaccines and as the epitope for monoclonal antibody therapies targeting cancers such as epithelial ovarian carcinoma (EOC). This domain is expressed primarily in ovarian tissue prior to menopause and is overexpressed in the majority of EOC tumors but largely absent from postmenopausal ovaries and other adult tissues. The principal mechanism is to elicit an anti-tumor immune response either via vaccination (to induce antigen-specific antibodies and T-helper cell immunity) or monoclonal antibodies (to directly target and inhibit tumor cells expressing AMHR2-ED). AMHR2-ED vaccination is believed to stimulate CD4+ T cell activation, induce B cell production of anti-AMHR2-ED IgG, and lead to tumor cell apoptosis via the Bax/caspase-3 pathway. Preclinical animal studies have shown that both vaccine and antibody approaches against AMHR2-ED can suppress tumor growth and improve survival, with a favorable safety profile. The vaccine formulation under development uses recombinant AMHR2-ED combined with adjuvants like AddaVax for human application. The approach is primarily being tested for ovarian cancer prevention and therapy, especially in BRCA1/2 mutation carriers at high risk for EOC, with considerations also for endometrial and possibly prostate cancers[2][3][6][8][11][13].

Other names

Anti-Müllerian hormone receptor type II extracellular domainanti-Müllerian hormone receptor 2 EDAMHR2 extracellular domainAMHR-2 extracellular domainAMHR 2 extracellular domain